U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Resectable Hepatocellular Carcinoma

MedGen UID:
163587
•Concept ID:
C0863194
•
Neoplastic Process
Synonyms: Hepatocellular Carcinoma, Resectable; Resectable Carcinoma of Liver Cell; Resectable Carcinoma of the Liver Cell; Resectable Hepatoma; Resectable Liver Cell Carcinoma

Definition

A hepatocellular carcinoma that is amenable to surgical resection. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVResectable Hepatocellular Carcinoma

Professional guidelines

PubMed

An Overview of Clinical Trials in the Treatment of Resectable Hepatocellular Carcinoma.
Nevarez NM, Chang GY, Yopp AC
Surg Oncol Clin N Am 2023 Jan;32(1):101-117. Epub 2022 Nov 3 doi: 10.1016/j.soc.2022.07.008. PMID: 36410911
Adjuvant treatment strategy after curative resection for hepatocellular carcinoma.
Zhang W, Zhang B, Chen XP
Front Med 2021 Apr;15(2):155-169. Epub 2021 Mar 23 doi: 10.1007/s11684-021-0848-3. PMID: 33754281
Treatment of non-resectable hepatocellular carcinoma.
Han KH, Lee JT, Seong J
J Gastroenterol Hepatol 2002 Dec;17 Suppl 3:S424-7. doi: 10.1046/j.1440-1746.17.s3.39.x. PMID: 12472975

Recent clinical studies

Etiology

Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial.
Marron TU, Fiel MI, Hamon P, Fiaschi N, Kim E, Ward SC, Zhao Z, Kim J, Kennedy P, Gunasekaran G, Tabrizian P, Doroshow D, Legg M, Hammad A, Magen A, Kamphorst AO, Shareef M, Gupta NT, Deering R, Wang W, Wang F, Thanigaimani P, Mani J, Troncoso L, Tabachnikova A, Chang C, Akturk G, Buckup M, Hamel S, Ioannou G, Hennequin C, Jamal H, Brown H, Bonaccorso A, Labow D, Sarpel U, Rosenbloom T, Sung MW, Kou B, Li S, Jankovic V, James N, Hamon SC, Cheung HK, Sims JS, Miller E, Bhardwaj N, Thurston G, Lowy I, Gnjatic S, Taouli B, Schwartz ME, Merad M
Lancet Gastroenterol Hepatol 2022 Mar;7(3):219-229. Epub 2022 Jan 20 doi: 10.1016/S2468-1253(21)00385-X. PMID: 35065058Free PMC Article
Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial.
Kaseb AO, Hasanov E, Cao HST, Xiao L, Vauthey JN, Lee SS, Yavuz BG, Mohamed YI, Qayyum A, Jindal S, Duan F, Basu S, Yadav SS, Nicholas C, Sun JJ, Singh Raghav KP, Rashid A, Carter K, Chun YS, Tzeng CD, Sakamuri D, Xu L, Sun R, Cristini V, Beretta L, Yao JC, Wolff RA, Allison JP, Sharma P
Lancet Gastroenterol Hepatol 2022 Mar;7(3):208-218. Epub 2022 Jan 20 doi: 10.1016/S2468-1253(21)00427-1. PMID: 35065057Free PMC Article
Adjuvant treatment strategy after curative resection for hepatocellular carcinoma.
Zhang W, Zhang B, Chen XP
Front Med 2021 Apr;15(2):155-169. Epub 2021 Mar 23 doi: 10.1007/s11684-021-0848-3. PMID: 33754281
Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled Study.
Wei X, Jiang Y, Zhang X, Feng S, Zhou B, Ye X, Xing H, Xu Y, Shi J, Guo W, Zhou D, Zhang H, Sun H, Huang C, Lu C, Zheng Y, Meng Y, Huang B, Cong W, Lau WY, Cheng S
J Clin Oncol 2019 Aug 20;37(24):2141-2151. Epub 2019 Jul 8 doi: 10.1200/JCO.18.02184. PMID: 31283409Free PMC Article
Primary liver cancers.
Weimann A, Oldhafer KJ, Pichlmayr R
Curr Opin Oncol 1995 Jul;7(4):387-96. doi: 10.1097/00001622-199507000-00017. PMID: 7578390

Diagnosis

Contrast-enhanced ultrasound for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.
Fraquelli M, Nadarevic T, Colli A, Manzotti C, Giljaca V, Miletic D, Štimac D, Casazza G
Cochrane Database Syst Rev 2022 Sep 2;9(9):CD013483. doi: 10.1002/14651858.CD013483.pub2. PMID: 36053210Free PMC Article
Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial.
Xia Y, Tang W, Qian X, Li X, Cheng F, Wang K, Zhang F, Zhang C, Li D, Song J, Zhang H, Zhao J, Yao A, Wu X, Wu C, Ji G, Liu X, Zhu F, Qin L, Xiao X, Deng Z, Kong X, Li S, Yu Y, Xi W, Deng W, Qi C, Liu H, Pu L, Wang P, Wang X
J Immunother Cancer 2022 Apr;10(4) doi: 10.1136/jitc-2022-004656. PMID: 35379737Free PMC Article
Computed tomography for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.
Nadarevic T, Giljaca V, Colli A, Fraquelli M, Casazza G, Miletic D, Štimac D
Cochrane Database Syst Rev 2021 Oct 6;10(10):CD013362. doi: 10.1002/14651858.CD013362.pub2. PMID: 34611889Free PMC Article
Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled Study.
Wei X, Jiang Y, Zhang X, Feng S, Zhou B, Ye X, Xing H, Xu Y, Shi J, Guo W, Zhou D, Zhang H, Sun H, Huang C, Lu C, Zheng Y, Meng Y, Huang B, Cong W, Lau WY, Cheng S
J Clin Oncol 2019 Aug 20;37(24):2141-2151. Epub 2019 Jul 8 doi: 10.1200/JCO.18.02184. PMID: 31283409Free PMC Article
Neoadjuvant and adjuvant therapies for resectable hepatocellular carcinoma (HCC) and palliation strategies.
Wildi S, Kadry Z, Clavien PA
Swiss Surg 2002;8(2):61-6. doi: 10.1024/1023-9332.8.2.61. PMID: 12013692

Therapy

Adjuvant and Neoadjuvant Treatments for Resectable Hepatocellular Carcinoma.
Crook CJ, Li D
Curr Oncol Rep 2023 Oct;25(10):1191-1201. Epub 2023 Sep 9 doi: 10.1007/s11912-023-01455-9. PMID: 37688739Free PMC Article
Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial.
Xia Y, Tang W, Qian X, Li X, Cheng F, Wang K, Zhang F, Zhang C, Li D, Song J, Zhang H, Zhao J, Yao A, Wu X, Wu C, Ji G, Liu X, Zhu F, Qin L, Xiao X, Deng Z, Kong X, Li S, Yu Y, Xi W, Deng W, Qi C, Liu H, Pu L, Wang P, Wang X
J Immunother Cancer 2022 Apr;10(4) doi: 10.1136/jitc-2022-004656. PMID: 35379737Free PMC Article
Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial.
Marron TU, Fiel MI, Hamon P, Fiaschi N, Kim E, Ward SC, Zhao Z, Kim J, Kennedy P, Gunasekaran G, Tabrizian P, Doroshow D, Legg M, Hammad A, Magen A, Kamphorst AO, Shareef M, Gupta NT, Deering R, Wang W, Wang F, Thanigaimani P, Mani J, Troncoso L, Tabachnikova A, Chang C, Akturk G, Buckup M, Hamel S, Ioannou G, Hennequin C, Jamal H, Brown H, Bonaccorso A, Labow D, Sarpel U, Rosenbloom T, Sung MW, Kou B, Li S, Jankovic V, James N, Hamon SC, Cheung HK, Sims JS, Miller E, Bhardwaj N, Thurston G, Lowy I, Gnjatic S, Taouli B, Schwartz ME, Merad M
Lancet Gastroenterol Hepatol 2022 Mar;7(3):219-229. Epub 2022 Jan 20 doi: 10.1016/S2468-1253(21)00385-X. PMID: 35065058Free PMC Article
Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial.
Kaseb AO, Hasanov E, Cao HST, Xiao L, Vauthey JN, Lee SS, Yavuz BG, Mohamed YI, Qayyum A, Jindal S, Duan F, Basu S, Yadav SS, Nicholas C, Sun JJ, Singh Raghav KP, Rashid A, Carter K, Chun YS, Tzeng CD, Sakamuri D, Xu L, Sun R, Cristini V, Beretta L, Yao JC, Wolff RA, Allison JP, Sharma P
Lancet Gastroenterol Hepatol 2022 Mar;7(3):208-218. Epub 2022 Jan 20 doi: 10.1016/S2468-1253(21)00427-1. PMID: 35065057Free PMC Article
Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled Study.
Wei X, Jiang Y, Zhang X, Feng S, Zhou B, Ye X, Xing H, Xu Y, Shi J, Guo W, Zhou D, Zhang H, Sun H, Huang C, Lu C, Zheng Y, Meng Y, Huang B, Cong W, Lau WY, Cheng S
J Clin Oncol 2019 Aug 20;37(24):2141-2151. Epub 2019 Jul 8 doi: 10.1200/JCO.18.02184. PMID: 31283409Free PMC Article

Prognosis

Neoadjuvant therapies in resectable hepatocellular carcinoma: Exploring strategies to improve prognosis.
Ma YN, Jiang X, Song P, Tang W
Biosci Trends 2024 Mar 19;18(1):21-41. Epub 2024 Feb 20 doi: 10.5582/bst.2023.01436. PMID: 38382930
Neoadjuvant immunotherapy for resectable hepatocellular carcinoma: a systematic review and meta-analysis.
Han YH, Bo JQ, Liu LX
Eur Rev Med Pharmacol Sci 2023 Aug;27(15):7134-7147. doi: 10.26355/eurrev_202308_33287. PMID: 37606124
Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial.
Xia Y, Tang W, Qian X, Li X, Cheng F, Wang K, Zhang F, Zhang C, Li D, Song J, Zhang H, Zhao J, Yao A, Wu X, Wu C, Ji G, Liu X, Zhu F, Qin L, Xiao X, Deng Z, Kong X, Li S, Yu Y, Xi W, Deng W, Qi C, Liu H, Pu L, Wang P, Wang X
J Immunother Cancer 2022 Apr;10(4) doi: 10.1136/jitc-2022-004656. PMID: 35379737Free PMC Article
Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled Study.
Wei X, Jiang Y, Zhang X, Feng S, Zhou B, Ye X, Xing H, Xu Y, Shi J, Guo W, Zhou D, Zhang H, Sun H, Huang C, Lu C, Zheng Y, Meng Y, Huang B, Cong W, Lau WY, Cheng S
J Clin Oncol 2019 Aug 20;37(24):2141-2151. Epub 2019 Jul 8 doi: 10.1200/JCO.18.02184. PMID: 31283409Free PMC Article
Neoadjuvant and adjuvant therapies for resectable hepatocellular carcinoma (HCC) and palliation strategies.
Wildi S, Kadry Z, Clavien PA
Swiss Surg 2002;8(2):61-6. doi: 10.1024/1023-9332.8.2.61. PMID: 12013692

Clinical prediction guides

Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients.
Yang X, Chen B, Wang Y, Wang Y, Long J, Zhang N, Xue J, Xun Z, Zhang L, Cheng J, Lei J, Sun H, Li Y, Lin J, Xie F, Wang D, Pan J, Hu K, Guan M, Huo L, Shi J, Yu L, Zhou L, Zhou J, Lu Z, Yang X, Mao Y, Sang X, Lu Y, Zhao H
Hepatol Int 2023 Jun;17(3):709-719. Epub 2023 Feb 8 doi: 10.1007/s12072-022-10480-y. PMID: 36753026Free PMC Article
Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial.
Xia Y, Tang W, Qian X, Li X, Cheng F, Wang K, Zhang F, Zhang C, Li D, Song J, Zhang H, Zhao J, Yao A, Wu X, Wu C, Ji G, Liu X, Zhu F, Qin L, Xiao X, Deng Z, Kong X, Li S, Yu Y, Xi W, Deng W, Qi C, Liu H, Pu L, Wang P, Wang X
J Immunother Cancer 2022 Apr;10(4) doi: 10.1136/jitc-2022-004656. PMID: 35379737Free PMC Article
Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial.
Marron TU, Fiel MI, Hamon P, Fiaschi N, Kim E, Ward SC, Zhao Z, Kim J, Kennedy P, Gunasekaran G, Tabrizian P, Doroshow D, Legg M, Hammad A, Magen A, Kamphorst AO, Shareef M, Gupta NT, Deering R, Wang W, Wang F, Thanigaimani P, Mani J, Troncoso L, Tabachnikova A, Chang C, Akturk G, Buckup M, Hamel S, Ioannou G, Hennequin C, Jamal H, Brown H, Bonaccorso A, Labow D, Sarpel U, Rosenbloom T, Sung MW, Kou B, Li S, Jankovic V, James N, Hamon SC, Cheung HK, Sims JS, Miller E, Bhardwaj N, Thurston G, Lowy I, Gnjatic S, Taouli B, Schwartz ME, Merad M
Lancet Gastroenterol Hepatol 2022 Mar;7(3):219-229. Epub 2022 Jan 20 doi: 10.1016/S2468-1253(21)00385-X. PMID: 35065058Free PMC Article
Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled Study.
Wei X, Jiang Y, Zhang X, Feng S, Zhou B, Ye X, Xing H, Xu Y, Shi J, Guo W, Zhou D, Zhang H, Sun H, Huang C, Lu C, Zheng Y, Meng Y, Huang B, Cong W, Lau WY, Cheng S
J Clin Oncol 2019 Aug 20;37(24):2141-2151. Epub 2019 Jul 8 doi: 10.1200/JCO.18.02184. PMID: 31283409Free PMC Article
Systematic review of neoadjuvant transarterial chemoembolization for resectable hepatocellular carcinoma.
Chua TC, Liauw W, Saxena A, Chu F, Glenn D, Chai A, Morris DL
Liver Int 2010 Feb;30(2):166-74. Epub 2009 Nov 13 doi: 10.1111/j.1478-3231.2009.02166.x. PMID: 19912531

Recent systematic reviews

Neoadjuvant immunotherapy for resectable hepatocellular carcinoma: a systematic review and meta-analysis.
Han YH, Bo JQ, Liu LX
Eur Rev Med Pharmacol Sci 2023 Aug;27(15):7134-7147. doi: 10.26355/eurrev_202308_33287. PMID: 37606124
Contrast-enhanced ultrasound for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.
Fraquelli M, Nadarevic T, Colli A, Manzotti C, Giljaca V, Miletic D, Štimac D, Casazza G
Cochrane Database Syst Rev 2022 Sep 2;9(9):CD013483. doi: 10.1002/14651858.CD013483.pub2. PMID: 36053210Free PMC Article
Magnetic resonance imaging for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.
Nadarevic T, Colli A, Giljaca V, Fraquelli M, Casazza G, Manzotti C, Štimac D, Miletic D
Cochrane Database Syst Rev 2022 May 6;5(5):CD014798. doi: 10.1002/14651858.CD014798.pub2. PMID: 35521901Free PMC Article
Computed tomography for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.
Nadarevic T, Giljaca V, Colli A, Fraquelli M, Casazza G, Miletic D, Štimac D
Cochrane Database Syst Rev 2021 Oct 6;10(10):CD013362. doi: 10.1002/14651858.CD013362.pub2. PMID: 34611889Free PMC Article
Systematic review of neoadjuvant transarterial chemoembolization for resectable hepatocellular carcinoma.
Chua TC, Liauw W, Saxena A, Chu F, Glenn D, Chai A, Morris DL
Liver Int 2010 Feb;30(2):166-74. Epub 2009 Nov 13 doi: 10.1111/j.1478-3231.2009.02166.x. PMID: 19912531

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...